Two Or More Nitrogen Atoms Bonded Directly To The Cyclohexyl Ring Patents (Class 514/36)
  • Patent number: 11399545
    Abstract: A method is provided for cultivating soybean or corn. Also provided is a method for controlling insect pests in a field of soybean or corn. By these methods, insect pests in the fields of soybean or corn can be controlled. Therefore, a good yield of corn or soybean can been obtained.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: August 2, 2022
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Naoya Akizuki, Atsushi Iwata, Yasutaka Shimokawatoko
  • Patent number: 11110054
    Abstract: The present invention provides stable, ready-to-use injectable pharmaceutical compositions, comprising the combination of neostigmine, glycopyrrolate, a stabilizing amount of one or more aminopolycarboxylic acids, and a pharmaceutically acceptable liquid vehicle. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, ethylenediaminetetraacetic acid (EDTA) and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: September 7, 2021
    Assignee: SLAYBACK PHARMA LLC
    Inventors: Rahul Dhulaji Bhise, Ajay Kumar Singh, Mahadeo Vasant Mahadik, Ashish Anilrao Dubewar, Molugu Prashanth Reddy
  • Patent number: 10730905
    Abstract: Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides of general formula I, where R is selected from the group comprising furan-2-yl, furan-3-yl, benzofuran-2-yl, methylsulfanyl, methoxy, amino, dimethylamino, methyl or chloro, and pharmaceutically acceptable salt thereof, their optical isomers and mixtures of such optical isomers.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: August 4, 2020
    Assignees: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I., UNIVERZITA PALACKEHO V OLOMOUCI
    Inventors: Michal Hocek, Anna Tokarenko, Sabina Smolen, Marian Hajduch, Petr Dzubak
  • Patent number: 10456354
    Abstract: The present invention provides stable, ready-to-use injectable pharmaceutical compositions, comprising the combination of neostigmine, glycopyrrolate, a stabilizing amount of one or more aminopolycarboxylic acids, and a pharmaceutically acceptable liquid vehicle. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, ethylenediaminetetraacetic acid (EDTA) and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: October 29, 2019
    Assignee: SLAYBACK PHARMA LLC
    Inventors: Rahul Dhulaji Bhise, Ajay Kumar Singh, Mahadeo Vasant Mahadik, Ashish Anilrao Dubewar, Molugu Prashanth Reddy
  • Patent number: 10034887
    Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: July 31, 2018
    Assignee: M.G. THERAPEUTICS, LTD.
    Inventors: Yair Alster, Omer Rafaeli, K. Angela MacFarlane, Cary Reich, Shimon Amselem, Doron Friedman
  • Patent number: 9067032
    Abstract: The present invention regards a novel administration form and a novel administration regime useful in the treatment and prevention of a bacterial lung infection in patient in need thereof, in particular by providing a composition useful for aerosolization of a highly concentrated solution of aminoglycosides such as Tobramycin.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: June 30, 2015
    Assignee: XELLIA PHARMACEUTICALS APS
    Inventor: Thomas Norling
  • Patent number: 8999942
    Abstract: In some aspects, the present invention provides aminoglycoside derivatives thereof that exhibit antibacterial activity. In some aspects, the aminoglycoside derivatives comprise compounds consisting of (a) an ammoglycoside group and (b) at least one hydrophobic carbamate and alkoxy group to the primary or secondary hydroxy position of the aminolvcoside group and salts thereof. Additionally, methods of treating and preventing bacterial infections using the aminoglycoside derivatives are also provided.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: April 7, 2015
    Assignee: University of Manitoba
    Inventors: Frank Schweizer, Smritilekha Bera, George Zhanel
  • Publication number: 20150093443
    Abstract: Compositions having a drug-loaded microparticle and bone cement and methods of making such compositions are disclosed. Also disclosed are methods of employing such compositions for the treatment of injected joint spaces and bone disease.
    Type: Application
    Filed: September 29, 2014
    Publication date: April 2, 2015
    Inventors: Victoria Maskiewicz, Gary Botimer, Serkan Inceoglu
  • Publication number: 20150086604
    Abstract: Biodegradable polymer-coated surgical meshes formed into pouches are described for use with cardiac rhythm management devices (CRMs) and other implantable medical devices. Such meshes are formed into a receptacle, e.g., a pouch or other covering, capable of encasing, surrounding and/or holding the cardiac rhythm management device or other implantable medical device for the purpose of securing it in position, inhibiting or reducing bacterial growth, providing pain relief and/or inhibiting scarring or fibrosis on or around the CRM or other implantable medical device. Preferred embodiments include surgical mesh pouches coated with one or more biodegradable polymers that can act as a stiffening agent by coating the filaments or fibers of the mesh to temporarily immobilize the contact points of those filaments or fibers and/or by increasing the stiffness of the mesh by at least 1.1 times its original stiffness.
    Type: Application
    Filed: September 23, 2013
    Publication date: March 26, 2015
    Inventors: Fatima Buevich, Frank Do, William McJames, Satish Pulapura, William Edelman, Arikha Moses, Mason Diamond, Shari Timothy
  • Publication number: 20150071982
    Abstract: The invention provides compositions comprising a plurality of polymer layers for preventing or inhibiting microbial infections. Specifically, the invention provides a combination of a cationic polymer layer that resists adhesion of a microbe to its surface and an anionic polymer layer that releases a cationic anti-microbial agent in response to a change in pH or electrostatic balance.
    Type: Application
    Filed: September 8, 2014
    Publication date: March 12, 2015
    Inventors: Hyun-Su Lee, David M. Eckmann, Russell Composto
  • Patent number: 8927460
    Abstract: Described are agrochemical compositions, comprising (a) esters and/or amides of pyroglutamic acid, and (b) biocides. The compositions are clear and exhibit an improved stability even when stored at temperatures between 5° and 40° C. over a longer period.
    Type: Grant
    Filed: December 6, 2010
    Date of Patent: January 6, 2015
    Assignee: Cognis IP Management GmbH
    Inventors: Joaquin Bigorra Llosas, Stéphanie Merlet, Ramon Valls, Javier Raya
  • Publication number: 20140371166
    Abstract: An antibiotic composition for the treatment of bacterial infections, especially in the respiratory tract is provided. The antibiotic composition may include a mixture of gentamicin as active pharmaceutical ingredient (API), and a micronized poloxamer composition as excipient. Micronized poloxamer composition may be produced by mixing poloxamer 188 and poloxamer 407 in a suitable apparatus where a low-frequency acoustic field may be applied to facilitate mixing. Antibiotic composition may be obtained in powder form, or in solution, and may be administered by inhalation or irrigation. In other embodiments, a topical formulation of the antibiotic inhalation or irrigation composition may be produced. In some embodiments, other suitable poloxamers, or sugar alcohols may be employed as excipients. Due to the synergistic effect of micronized poloxamer composition, antibiotic composition may provide improved solubility and bioavailability of gentamicin, thus decreasing side effects and time of treatment.
    Type: Application
    Filed: June 14, 2013
    Publication date: December 18, 2014
    Applicant: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
    Inventor: Daniel Banov
  • Publication number: 20140323422
    Abstract: The invention relates to anionic conjugates of glycosylated bacterial metabolites that may be used to mimic the structure and/or activity of the anionic bioactive molecules known as glycosaminoglycans (GAGs). The invention also relates to processes for the preparation of the conjugates. Such conjugates are useful in the prophylaxis and/or treatment of disease conditions and in particular chronic disease conditions such as inflammatory (including allergic) diseases, metastatic cancers and infection by pathogenic agents including bacteria, viruses or parasites.
    Type: Application
    Filed: July 10, 2014
    Publication date: October 30, 2014
    Inventors: Warren Charles KETT, Yugang CHEN
  • Publication number: 20140274932
    Abstract: This disclosure relates generally to aminoglycoside derivatives of Formula (I) as described herein. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating bacterial infections by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Anthony J. Ricci, Robert J. Greenhouse, Alan G. Cheng
  • Publication number: 20140256658
    Abstract: The present invention describes antibiotic conjugates. These single drug entities are formed connecting one antibiotic with another antibiotic. Upon topical application to the eye, the conjugate hybrid would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 11, 2014
    Applicant: Allergan, Inc.
    Inventors: Santosh C. Sinha, Smita S. Bhat, Ken Chow, LIMING WANG, MICHAEL E. GARST, MAYSSA ATTAR, BRANDON D. SWIFT
  • Patent number: 8822424
    Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R8 and R9 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: September 2, 2014
    Assignee: Achaogen, Inc.
    Inventors: James Bradley Aggen, Adam Aaron Goldblum, Martin Sheringham Linsell, Paola Dozzo, Heinz Ernst Moser, Darin James Hildebrandt, Micah James Gliedt
  • Publication number: 20140206637
    Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD an inhibitor of NMD and a nonsense suppressor, whereby degradation of NMD susceptible mRNA is decreased and translation termination at a misplaced nonsense codon is blocked.
    Type: Application
    Filed: June 13, 2012
    Publication date: July 24, 2014
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Tsafi Pe'ery, Michael B. Mathews, Mainul Hoque, Hartmut M. Hanauske-Abel
  • Patent number: 8765698
    Abstract: Products and methods are provided for the restoring the endogenous expression of theta-defensins, such as retrocyclin-1, in mamallian cells. The present invention also includes products and methods for inhibiting sexually transmitted virus entry, e.g., HIV-1 virus entry, into a mammalian cell via, for example, administering to a subject an amount of a read-through mediating agent sufficient to induce exogenous expression of an amount of retrocyclin nonapeptides in the mammalian cell.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: July 1, 2014
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventor: Alexander M. Cole
  • Publication number: 20140179518
    Abstract: The present invention relates to pesticidal mixtures comprising as active components 1) at least one cyanosulfoximine compound I of the formula I wherein R1, R2 and G are defined as in the description; and 2) at least one fungicidal compounds II selected from azoles, strobilurins, carboxamides, carbamates, heterocyclic and various other compounds as defined in the description, in synergistically effective amounts. The invention relates further to methods and use of these mixtures for combating insects, arachnids or nematodes and harmful fungis in and on plants, and for protecting such plants being infested with pests, especially also for protecting seeds.
    Type: Application
    Filed: December 20, 2013
    Publication date: June 26, 2014
    Applicant: BASF SE
    Inventors: Delphine BREUNINGER, Henricus Maria Martinus BASTIAANS, Wolfgang VON DEYN, Matthias POHLMAN, Juergen LANGEWALD, Egon HADEN
  • Publication number: 20140148398
    Abstract: Compounds useful for the treatment of giardiasis are described.
    Type: Application
    Filed: October 12, 2011
    Publication date: May 29, 2014
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Service, UNIVERSITY OF MARYLAND, COLLEGE PARK
    Inventors: Wei Zheng, Catherine Chen, Juan Jose Marugan, Noel Southall, Christopher P. Austin, Andrey Galkin, Liudmila Kulakova, Osnat Herzberg
  • Patent number: 8735363
    Abstract: The present invention relates to a method for preparation of heparin silver, to use of heparin silver in manufacture of medicine for treating burns and/or scalds, to a method of using heparin silver to treat burns and/or scalds, and to a topical preparation containing heparin silver for treating burns and/or scalds. The heparin silver product prepared according to the method of the present invention has a high purity and less impurity. The animal test proved that the medicine made by using heparin silver exhibited effects of accelerating wound healing and reducing scar formation.
    Type: Grant
    Filed: April 20, 2006
    Date of Patent: May 27, 2014
    Inventors: Peixue Ling, Yanli He, Jianying Chen
  • Patent number: 8729035
    Abstract: This invention concerns compounds with the formula: in which: R1?OH or NH2; OR2, OR3, OR4 and OR5 are alcohol, ether, ester, carbonate, carbamate, sulphonate or sulphamate groups; and if R5?H if R2?R3?R4, then R2, R3 and R4?H; if R2?H, then R3?H and R4?H; if R3?H, then R2?H and R4?H; if R4?H, then R2?H and R3?H; if R5?H if R2=H, then R3?H and R4?H; if R3?H, then R2?H and R4?H; if R4?H, then R2?H and R3?H, their use as antibiotic agents and the process for synthesizing them.
    Type: Grant
    Filed: January 22, 2009
    Date of Patent: May 20, 2014
    Assignee: Universite Joseph Fourier
    Inventors: Jean-Luc Decout, Isabelle Baussanne, Jerome Desire, Jean-Marc Paris
  • Patent number: 8658606
    Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 or R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: February 25, 2014
    Assignee: Achaogen, Inc.
    Inventors: Adam Aaron Goldblum, Paola Dozzo, James Bradley Aggen, Martin Sheringham Linsell
  • Patent number: 8653041
    Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein Q1 and Q2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: February 18, 2014
    Assignee: Achaogen, Inc.
    Inventors: Adam Aaron Goldblum, Paola Dozzo, Timothy Robert Kane, James Bradley Aggen, Martin Sheringham Linsell, Darin James Hildebrandt, Micah James Gliedt
  • Patent number: 8653042
    Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: February 18, 2014
    Assignee: Achaogen, Inc.
    Inventors: Paola Dozzo, Adam Aaron Goldblum, James Bradley Aggen, Martin Sheringham Linsell
  • Publication number: 20140038914
    Abstract: This invention relates to a compound of Formula 1A: or a pharmaceutically acceptable salt thereof; wherein R1 to R4, R7, R9 to R12 and Y are as defined herein. The invention further relates to pharmaceutical composition comprising said compound or a pharmaceutically acceptable salt thereof; and method of using same for reducing or reversing bacterial resistance to at least one aminoglycoside antibiotic.
    Type: Application
    Filed: January 17, 2012
    Publication date: February 6, 2014
    Applicant: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
    Inventors: Karine Auclair, Kenward Vong
  • Publication number: 20130330400
    Abstract: Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.
    Type: Application
    Filed: May 21, 2013
    Publication date: December 12, 2013
    Applicant: Insmed Incorporated
    Inventor: Insmed Incorporated
  • Patent number: 8598131
    Abstract: The present invention regards a novel administration form and a novel administration regime useful in the treatment and prevention of a bacterial lung infection in patient in need thereof, in particular by providing a composition useful for aerosolization of a highly concentrated solution of aminoglycosides such as Tobramycin.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: December 3, 2013
    Assignee: Xellia Pharmaceuticals APS
    Inventor: Thomas Norling
  • Patent number: 8551456
    Abstract: A combination therapy for treating a bacterial biofilm comprises a therapeutically effective amount of an antibiotic comprising an aminoglycoside or tetracycline, or a combination of two or more thereof, and a cationic porphyrin in an amount effective for enhancing the effectiveness of the antibiotic in treating the bacterial biofilm. A method of treating a bacterial biofilm comprising Pseudomonas aeruginosa comprises contacting the bacterial biofilm with a combination therapy comprising a therapeutically effective amount of an antibiotic, and a cationic porphyrin in an amount effective for enhancing the effectiveness of the antibiotic in treating the bacterial biofilm. A method of treating a bacterial biofilm comprising Pseudomonas aeruginosa in a patient comprises administering to the patient a combination therapy comprising a therapeutically effective amount of an antibiotic, and a cationic porphyrin in an amount effective for enhancing the effectiveness of the antibiotic in treating the bacterial biofilm.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: October 8, 2013
    Assignee: University of Dayton
    Inventors: Jayne Robinson, Tracy Collins
  • Patent number: 8524675
    Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I) or (II): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2, R3, R11 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: September 3, 2013
    Assignee: Achaogen, Inc.
    Inventors: Paola Dozzo, Adam Aaron Goldblum, James Bradley Aggen, Martin Sheringham Linsell
  • Publication number: 20130196900
    Abstract: The present invention provides compounds and compositions that enhance the innate immune system. The present invention comprises methods of preventing, treating or ameliorating an infectious disease comprising administering said compounds to a subject. The invention also comprises methods of formulation and administration of said compounds.
    Type: Application
    Filed: January 18, 2013
    Publication date: August 1, 2013
    Applicant: MONTANA STATE UNIVERSITY
    Inventor: MONTANA STATE UNIVERSITY
  • Patent number: 8492334
    Abstract: Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing one or more diseases or disorders of the eye, and methods of making and using thereof, are described. In a preferred embodiment, the microparticle compositions contain one or more active agents useful for managing elevated intraocular pressure (IOP) in the eye. Relatively hydrophilic, and preferably carboxylated, polymeric materials such as PLGA are used for a drug such as timolol maleate, which is relatively water soluble, to increase drug loading. Higher molecular weight polymers, as well as the ratio of LA (which has a longer degradation time, up to one to two years) to GA (which has a short degradation time, as short as a few days to a week), are used to provide release over a longer period of time.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: July 23, 2013
    Assignees: Yale University, University of Iowa Research Foundation
    Inventors: Erin Lavik, Young H. Kwon, Markus Kuehn, Sandeep Saluja, James Bertram, John Huang
  • Patent number: 8492354
    Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R11 and R12 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: July 23, 2013
    Assignee: Achaogen, Inc.
    Inventors: Paola Dozzo, Adam Aaron Goldblum, James Bradley Aggen, Martin Sheringham Linsell
  • Patent number: 8481502
    Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q5, R1, R2, R3, Z1 and Z2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: July 9, 2013
    Assignee: Achaogen, Inc.
    Inventors: James Bradley Aggen, Paola Dozzo, Adam Aaron Goldblum, Darin James Hildebrandt, Timothy Robert Kane, Micah James Gliedt, Martin Sheringham Linsell
  • Publication number: 20130165397
    Abstract: The present invention relates to a novel pharmacological treatment of bacterial infectious diseases in humans. Specifically the invention relates to the use of apramycin of formula (I) or apramycin derivatives to treat bacterial infectious diseases in humans. It is demonstrated that apramycin surprisingly does not have the expected high level of toxicity observed with related aminoglycoside antibiotics but actually is even significantly less toxic than compounds already used in human medicine such as gentamicin.
    Type: Application
    Filed: September 12, 2011
    Publication date: June 27, 2013
    Applicants: ETH ZURICH, UNIVERSITY OF ZURICH
    Inventors: Erik Boettger, Andrea Vasella
  • Publication number: 20130157969
    Abstract: In some aspects, the present invention provides aminoglycoside derivatives thereof that exhibit antibacterial activity. In some aspects, the aminoglycoside derivatives comprise compounds consisting of (a) an ammoglycoside group and (b) at least one hydrophobic carbamate and alkoxy group to the primary or secondary hydroxy position of the aminolvcoside group and salts thereof.
    Type: Application
    Filed: April 5, 2011
    Publication date: June 20, 2013
    Inventors: Frank Schweizer, Smritilekha Bera, George Zhanel
  • Publication number: 20130102467
    Abstract: Described are agrochemical compositions, comprising (a) esters and/or amides of pyroglutamic acid, and (b) biocides. The compositions are clear and exhibit an improved stability even when stored at temperatures between 5° and 40° C. over a longer period.
    Type: Application
    Filed: December 6, 2010
    Publication date: April 25, 2013
    Applicant: COGNIS IP MANAGEMENT GMBH
    Inventors: Joaquin Bigorra Llosas, Stéphanie Merlet, Ramon Valls, Javier Raya
  • Patent number: 8426373
    Abstract: A pharmaceutical composition containing at least one ?-lactam antibiotic, at least one ion-chelating agent, at least one buffer component, and at least one aminoglycoside antibiotic.
    Type: Grant
    Filed: February 24, 2009
    Date of Patent: April 23, 2013
    Inventor: Hesheng Zhang
  • Patent number: 8399419
    Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Z1, Z2, Z3, Z4, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: March 9, 2011
    Date of Patent: March 19, 2013
    Assignee: Achaogen, Inc.
    Inventors: James Bradley Aggen, Martin Sheringham Linsell, Adam Aaron Goldblum, Darin James Hildebrandt, Timothy Robert Kane, Paola Dozzo, Micah James Gliedt, Stephen Hanessian, Alexandre Giguère, Justyna Grzyb, Juan Pablo Maianti
  • Publication number: 20130058983
    Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections.
    Type: Application
    Filed: August 3, 2012
    Publication date: March 7, 2013
    Inventor: Brett Hugh James Baker
  • Patent number: 8383596
    Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R8 and R9 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: February 26, 2013
    Assignee: Achaogen, Inc.
    Inventors: James Bradley Aggen, Adam Aaron Goldblum, Martin Sheringham Linsell, Paola Dozzo, Heinz Ernst Moser, Darin James Hildebrandt, Micah James Gliedt
  • Patent number: 8372813
    Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: February 12, 2013
    Assignee: Achaogen, Inc.
    Inventors: James Bradley Aggen, Martin Sheringham Linsell, Adam Aaron Goldblum, Darin James Hildebrandt, Timothy Robert Kane, Paola Dozzo, Micah James Gliedt, Heinz Ernst Moser
  • Patent number: 8367625
    Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: February 5, 2013
    Assignee: Achaogen, Inc.
    Inventors: James Bradley Aggen, Martin Sheringham Linsell, Adam Aaron Goldblum, Darin James Hildebrandt, Timothy Robert Kane, Paola Dozzo, Micah James Gliedt, Heinz Ernst Moser
  • Publication number: 20120301434
    Abstract: The present invention discloses polypeptides with antibacterial properties and use said polypeptides and/or polynucleotides encoding said polypeptides in the preparation of medicament for the treatment of infectious diseases. The inventors also provide vectors encoding and adapted for expression of the polypeptides and polynucleotides of the invention. The vectors may be used in the preparation of a medicament for the treatment of bacterial infections. Further, the vector of the invention may be used to reduce the load of bacteria in food and/or feed.
    Type: Application
    Filed: October 4, 2010
    Publication date: November 29, 2012
    Applicant: OSLO UNIVERSITETSSYKEHUS HF
    Inventors: Ragnhild Weel-Sneve, James Alexander Booth, Magnar Bjørås, Knut Ivan Kristiansen
  • Patent number: 8318685
    Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein Q1 and Q2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: November 27, 2012
    Assignee: Achaogen, Inc.
    Inventors: Adam Aaron Goldblum, Paola Dozzo, Timothy Robert Kane, James Bradley Aggen, Martin Sheringham Linsell, Darin James Hildebrandt, Micah James Gliedt
  • Publication number: 20120196791
    Abstract: Methods for treating a bacterial infection in a mammal in need thereof, and compositions related thereto, are disclosed, the methods comprising administering to the mammal an effective amount of an antibacterial aminoglycoside compound and a second antibacterial agent.
    Type: Application
    Filed: December 15, 2011
    Publication date: August 2, 2012
    Applicant: Achaogen, Inc.
    Inventors: Eliana Saxon Armstrong, Jon B. Bruss
  • Patent number: 8178501
    Abstract: The invention relates to a new pharmaceutical composition, a method of treatment of infection and also a process to prepare the composition. The infectious complications are important causes of morbidity and mortality. Hospital acquired pneumonia (HAP) remains the most severe nosocomial infection in intensive care units. Beta-lactams alone are always considered inadequate when P. aeruginosa and/or methicillin-resistant S. aureus are implicated as pathogens or copathognes. The present invention provides the desired empirical therapy for control of all bacterial infections. The invention provides antibiotic combination products for delivering at least two different antibiotics, through parenteral dosage form comprising protein-synthesis-inhibiting antibiotic which is amikacin or its sulphate salt and non-protein-synthesis-inhibiting antibiotic which is cefepime or its hydrochloride salt. The invention provides a total solution, against multiresistant P. aeruginosa, or Acinetobacter spp.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: May 15, 2012
    Assignee: Venus Remedies Limited
    Inventor: Manu Chaudhary
  • Patent number: 8168598
    Abstract: The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium Pseudomonas aeruginosa associated to lung diseases such as cystic fibrosis.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: May 1, 2012
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Chiara Malvolti, Raffaella Garzia
  • Patent number: 8133883
    Abstract: An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin/tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and optionally an aminoglycoside. The product may be in the form of a frozen composition that can be thawed for use. The product may also be in the form of a cryodesiccated powder that can be reconstituted by addition of an aqueous vehicle to reform a solution.
    Type: Grant
    Filed: February 24, 2011
    Date of Patent: March 13, 2012
    Assignee: Pfizer Inc.
    Inventors: Jonathan M. Cohen, Syed M Shah, Christian L. Ofslager, Mahdi B. Fawzi
  • Publication number: 20120021038
    Abstract: A wound spacer device comprising multiple beads connected by non-absorbable suture material is disclosed. The device can be applied, for example, by a first responder to an injured individual, or can be applied by a trauma treatment facility, such as a Level 2 medical unit. In typical embodiments the device allows for site-specific controlled elution of an antimicrobial agent, such as Tobramycin, including defined elution over a period of time, such as 48 or 72 hours.
    Type: Application
    Filed: September 23, 2011
    Publication date: January 26, 2012
    Applicant: Surmodics, Inc.
    Inventors: Tim M. Kloke, Steven J. Keough, Nathan Lockwood, Margaret R. Gardner, Robert W. Hergenrother, Ralph A. Chappa